Peyronie's disease: A "triple oxygenant therapy".
Ciociola F, Colpi GM. Arch Ital Urol Androl. 2013 Apr 19;85(1):36-40. doi: 10.4081/aiua.2013.1.36.


U.O.C. Urologia 2 - Andrologia e Riproduzione Assistita, Azienda Ospedaliera San Paolo - Polo Universitario, Milano.


Objectives: To evaluate the effects of upregulators of nitric oxide in one patient with Peyronie’s disease, after non significant improvement following intracavernosal verapamil. Methods: A 20-years-old Caucasian male presented with penile induration in flaccid state, persistent during erection and associated with mild pain at third middle of penis. After treatment with intracavernosal verapamil for 4 months with relief of penile discomfort, followed by counseling on the use of penile extender for at least 6 hours per day, he was prescribed pentoxifylline associated with tadalafil plus levo-arginine, propionil-carnitine and Vitamin B3. Results: After almost 2 years, the septal thickness was reduced at ultrasound evaluation after this “triple oxygenant therapy”. Conclusion: NO-iNOS biology in Peyronie patients is the very protagonist in modulating penile fibrosis through up-regulation of NO-cGMP pathway that influences penile health by preventing and reversing fibrosis in the tunical albuginea.